AlphAIAlphAI — Financial news for AI agents
finance.biggo.comOCT 292 min read$GILD

GILD Q3 FY2026 earnings call — BigGo Finance

Gilead Sciences reported Q3 2026 sales of $8.3B (+13% YoY), with base business up 16%. EPS was $2.55, up 15% YoY excluding a prior-year IP sale. HIV sales grew 18%, driven by BIKTARVY and DESCOVY. Guidance raised: FY2026 sales now $30.7B-$31.0B. Management expects 2028 HIV revenue growth despite IRA pricing impacts.

Original reporting
finance.biggo.com
Published Oct 29, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GILD
Bullish
high confidence
Mentioned
$GILD
Relevance
9/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$GILDBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to boost Gilead's stock price in the near term.

02

Market read

Strong earnings and guidance raise expectations for the biotech sector and may influence related stocks.

03

What to watch

Potential headwinds from the BIKTARVY IRA pricing impact could dampen future margins.

Relevance 9/10Novelty 9/10Timing: after-hours release

Background

Gilead Sciences held its Q3 FY2026 earnings call, presenting detailed financial and product updates.

Company-level read

Ticker impact

$GILDBullishHigh confidence
Context

Gilead reported Q3 FY2026 sales of $8.2B (+16% YoY) and raised FY2026 guidance, indicating strong growth.

Expected impact

likely upward pressure as investors price in higher sales and margins.

Evidence & confidence

Quarterly sales beat expectations, margin expansion, and optimistic outlook drive a bullish view.

Market effects

Sector

Biotech and pharma sector may see broader optimism from Gilead's strong performance.

Regional

U.S. healthcare stocks could rally in response to the earnings beat.

Global

International investors may adjust exposure to antiviral and HIV drug markets.

Counterpoint

What could challenge this read

If the market has already priced in the guidance raise, the stock may face a short-term pullback.

Key entities

  • company
    Gilead Sciences, Inc.

    Pharmaceutical company reporting Q3 FY2026 results.

Read at source← All news

StoryGilead beats Q3 2026 earnings, lifts full‑year sales outlook on strong HIV growth

Also covered by

6 outlets

Related articles

OCT 30
$GILDMedAI 8/10

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead Sciences (GILD) raised its 2026 sales outlook to $31B-$31.3B, citing strong Q3 growth. HIV revenues are expected to grow 12% in 2026, but Biktarvy faces a $1.5B revenue headwind in 2028 due to Medicare pricing. Q3 earnings beat estimates at $2.55 per share, with revenues of $8.3B. The company also detailed advancements in oncology and inflammation pipelines.

zacks.com3 min
OCT 30
$GILDHighAI 9/10

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead Sciences reported Q3 2026 adjusted earnings of $2.55 per share, beating estimates. Revenues rose 6.8% to $8.3B, driven by HIV drugs and Trodelvy. HIV sales grew 18% to $6.25B, while Trodelvy sales jumped 42% to $506M. GILD raised its 2026 product sales guidance to $31-$31.3B. Cell Therapy revenues declined 18% to $355M. Shares have gained 38.2% year to date.

zacks.com6 min